Business Wire

Blue Danube Systems First to Demonstrate Benefits of FDD Massive MIMO in Clustered Multi-Sector Deployments

Jaa

Blue Danube Systems, a provider of intelligent wireless access solutions that help mobile operators address the challenge of explosive data growth, today announced it has successfully expanded the commercial deployment of its massive MIMO solution to multiple clustered cell sites, demonstrating total capacity improvements for directly adjoining sectors on existing LTE networks using current smartphones.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222006158/en/

Blue Danube Systems First to Demonstrate Benefits of FDD Massive MIMO in Clustered Multi-Sector Depl ...

Blue Danube Systems First to Demonstrate Benefits of FDD Massive MIMO in Clustered Multi-Sector Deployments (Photo: Business Wire)

Despite the prevalent view that Massive MIMO systems will be central to 5G networks, it has not been clearly proven that the technology is deployable beyond isolated high-demand sectors where effects such as adjacent cell interference must be addressed. In fact, common digital-only Massive MIMO implementations typically operate as closed single-sector solutions, spilling unwanted Radio Frequency (RF) energy across cell edges and potentially degrading adjacent sector performance. In contrast, Blue Danube’s approach to Massive MIMO starts by assuring RF array coherency which in conjunction with digital processing uniquely enables the definition, placement and dynamic coordination of high precision beams that can be software engineered to minimize adjacent sector interference and actually improve clustered cell performance.

Using its BeamCraft™ 500 Massive MIMO systems, Blue Danube performed multi-sector beam optimization at two different sites within the FDD-LTE network at a US mobile operator. Leveraging the machine learning intelligence of the cloud-based software platform BeamPlanner™, RF patterns were generated to optimize and coordinate inter-cell and inter-sector performance. Using only two beams, improvements of 1.7 to 2.0X were demonstrated in total downlink capacity over both multi-sector locations. Additionally, critical cell edge locations saw a dramatic 7dB increase in signal quality due to BeamCraft’s precision beam control leading to 1.7X improvement in individual user download speed. Blue Danube further expects capacity improvements of 5X or more by increasing from two to four beams in future trials and will begin operation in March with a second mobile operator at a multi-sector dense urban location.

By combining precise dynamic beam control with open system interfaces, Blue Danube is engineering its Massive MIMO suite of products to interoperate with other industry network resources such as Self Optimized Network (SON), Centralized Radio Access Network (CRAN) and Open Network Application Platform (ONAP) software along with geolocation and mobile application driven analytics. Combined with BeamPlanner, these capabilities enable operators to use intelligence about their network and customer use to deliver the highest level of overall system-wide performance.

“We are excited to be the first in the industry to successfully demonstrate capacity improvement for clustered multi-sector Massive MIMO deployments,” said Mark Pinto, CEO of Blue Danube Systems. “Adding to our recent announcement of the first multi-band Massive MIMO products, we are making available powerful and flexible tools for operators to seamlessly insert 5G-ready technology into their existing LTE networks for substantial system-wide capacity gain.”

“Cell edge performance continues to be a major challenge for pure digital Massive MIMO systems,” said Shiv Panwar, Professor of Electrical Engineering at NYU and Director of the New York State Center for Advanced Technology in Telecommunications (CATT). “This is the very first demonstration of Massive MIMO performance in a clustered deployment. Blue Danube’s multi-sector BeamCraft results are very exciting and demonstrate that Massive MIMO is now viable for wide-scale adoption in FDD networks.”

“Until now, we have only seen Massive MIMO deployed on individual sectors, not on multiple sectors facing each other,” said Joe Madden, Founder and Principal Analyst at Mobile Experts. “Blue Danube’s results on clustered Massive MIMO deployments represent a critical milestone, provide compelling evidence that the technology can have broad impact across entire operator networks.”

About Blue Danube Systems

Blue Danube Systems is a privately held start-up backed by Sequoia Capital and Silver Lake along with other investors including AT&T. Blue Danube’s unique, award-winning technology combines intelligent software and hardware into a Massive MIMO solution that enables a significant increase in network capacity, utilizing existing infrastructure and today’s mobile devices. For more information, please visit www.bluedanube.com

Blue Danube Participation at Mobile World Congress 2018

Blue Danube will have representatives at Mobile World Congress from February 26 through March 1 in Barcelona. Blue Danube can be found in Hall 2, hospitality stand 2L10.

Contact information

Media Contacts for Blue Danube Systems:
US/North America:
Babel PR
Mike Newsom, 617-803-5385 (call or text)
mike@babelpr.com
or
EMEA:
Babel PR
Paul Campbell, +44 (0)7986.385.807
Paul@babelpr.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45Tiedote

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10Tiedote

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30Tiedote

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 20:37Tiedote

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10Tiedote

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme